Immunocore Historical Balance Sheet

IMCR Stock

USD 29.47 0.15 0.51%

Trend analysis of Immunocore Holdings balance sheet accounts such as Other Liabilities of 5.1 M or Net Tangible Assets of 336.1 M provides information on Immunocore Holdings' total assets, liabilities, and equity, which is the actual value of Immunocore Holdings to its prevalent stockholders. By breaking down trends over time using Immunocore Holdings balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Immunocore Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunocore Holdings is a good buy for the upcoming year.

Immunocore Holdings Inventory

5.72 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

About Immunocore Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Immunocore Holdings at a specified time, usually calculated after every quarter, six months, or one year. Immunocore Holdings Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunocore Holdings and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunocore currently owns. An asset can also be divided into two categories, current and non-current.

Immunocore Holdings Balance Sheet Chart

At this time, Immunocore Holdings' Non Currrent Assets Other are relatively stable compared to the past year. As of 03/27/2025, Long Term Debt is likely to grow to about 410.6 M, though Retained Earnings are likely to grow to (756 M).

Other Current Liab Total Current Liabilities Other Liab Net Tangible Assets

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Immunocore Holdings balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunocore Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from Immunocore Holdings' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Immunocore Holdings current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.At this time, Immunocore Holdings' Non Currrent Assets Other are relatively stable compared to the past year. As of 03/27/2025, Long Term Debt is likely to grow to about 410.6 M, though Retained Earnings are likely to grow to (756 M).

	2022	2023	2024	2025 (projected)
Total Current Liabilities	83.1M	139.0M	212.2M	222.8M
Other Current Liabilities	58.1M	114.3M	178.6M	187.5M

Total Current Liabilities Other Current Liab

Immunocore Holdings balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Property Plant Equipment	Other Current Assets	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Total Liab
Other Current Liab		0.96	-0.45	0.74	-0.91	0.76	0.25	0.67	0.9	0.98	0.43	0.47	0.98	0.53	0.81	0.6	-0.94	0.83	0.77	0.51	0.91	0.98	0.82	0.88	0.55	0.93
Total Current Liabilities	0.96		-0.38	0.63	-0.94	0.86	0.29	0.76	0.91	0.95	0.62	0.65	0.96	0.63	0.77	0.78	-0.88	0.79	0.88	0.52	0.9	0.95	0.8	0.86	0.34	0.92
Other Liab	-0.45	-0.38		-0.78	0.44	-0.31	-0.35	0.04	-0.48	-0.52	-0.02	0.0	-0.52	-0.37	-0.61	-0.16	0.62	-0.61	-0.32	-0.06	-0.39	-0.53	-0.62	-0.35	-0.51	-0.38
Net Tangible Assets	0.74	0.63	-0.78		-0.56	0.43	0.13	0.3	0.73	0.82	-0.07	-0.04	0.79	0.27	0.78	0.17	-0.89	0.79	0.41	0.4	0.65	0.8	0.72	0.63	0.82	0.67
Retained Earnings	-0.91	-0.94	0.44	-0.56		-0.86	-0.33	-0.75	-0.89	-0.85	-0.66	-0.66	-0.88	-0.76	-0.83	-0.79	0.85	-0.84	-0.9	-0.31	-0.76	-0.87	-0.89	-0.7	-0.28	-0.77
Accounts Payable	0.76	0.86	-0.31	0.43	-0.86		0.48	0.86	0.86	0.72	0.8	0.77	0.75	0.71	0.81	0.87	-0.73	0.81	0.95	0.37	0.64	0.73	0.82	0.57	0.11	0.66
Other Assets	0.25	0.29	-0.35	0.13	-0.33	0.48		0.29	0.33	0.2	0.44	0.19	0.25	0.32	0.35	0.26	-0.29	0.34	0.31	0.11	0.16	0.24	0.35	0.12	0.12	0.17
Net Receivables	0.67	0.76	0.04	0.3	-0.75	0.86	0.29		0.77	0.61	0.64	0.6	0.64	0.52	0.68	0.73	-0.63	0.68	0.81	0.37	0.51	0.61	0.64	0.47	0.11	0.55
Other Stockholder Equity	0.9	0.91	-0.48	0.73	-0.89	0.86	0.33	0.77		0.88	0.56	0.51	0.9	0.73	0.92	0.68	-0.93	0.91	0.83	0.41	0.72	0.89	0.93	0.66	0.45	0.75
Total Current Assets	0.98	0.95	-0.52	0.82	-0.85	0.72	0.2	0.61	0.88		0.35	0.43	1.0	0.45	0.79	0.56	-0.94	0.81	0.73	0.53	0.94	1.0	0.79	0.92	0.58	0.96
Property Plant Equipment	0.43	0.62	-0.02	-0.07	-0.66	0.8	0.44	0.64	0.56	0.35		0.92	0.41	0.79	0.39	0.92	-0.29	0.38	0.81	0.13	0.38	0.39	0.52	0.3	-0.42	0.37
Other Current Assets	0.47	0.65	0.0	-0.04	-0.66	0.77	0.19	0.6	0.51	0.43	0.92		0.47	0.64	0.34	0.91	-0.29	0.35	0.81	0.07	0.52	0.45	0.49	0.46	-0.43	0.5
Total Assets	0.98	0.96	-0.52	0.79	-0.88	0.75	0.25	0.64	0.9	1.0	0.41	0.47		0.49	0.79	0.61	-0.94	0.81	0.77	0.53	0.94	1.0	0.8	0.91	0.55	0.95
Short Long Term Debt Total	0.53	0.63	-0.37	0.27	-0.76	0.71	0.32	0.52	0.73	0.45	0.79	0.64	0.49		0.65	0.78	-0.52	0.63	0.76	0.08	0.3	0.48	0.77	0.2	-0.07	0.31
Total Stockholder Equity	0.81	0.77	-0.61	0.78	-0.83	0.81	0.35	0.68	0.92	0.79	0.39	0.34	0.79	0.65		0.53	-0.93	1.0	0.76	0.34	0.57	0.79	0.96	0.51	0.58	0.6
Property Plant And Equipment Net	0.6	0.78	-0.16	0.17	-0.79	0.87	0.26	0.73	0.68	0.56	0.92	0.91	0.61	0.78	0.53		-0.48	0.54	0.94	0.32	0.56	0.58	0.62	0.49	-0.26	0.57
Net Debt	-0.94	-0.88	0.62	-0.89	0.85	-0.73	-0.29	-0.63	-0.93	-0.94	-0.29	-0.29	-0.94	-0.52	-0.93	-0.48		-0.94	-0.7	-0.46	-0.79	-0.94	-0.9	-0.75	-0.7	-0.81
Cash	0.83	0.79	-0.61	0.79	-0.84	0.81	0.34	0.68	0.91	0.81	0.38	0.35	0.81	0.63	1.0	0.54	-0.94		0.77	0.35	0.6	0.81	0.96	0.54	0.59	0.63
Non Current Assets Total	0.77	0.88	-0.32	0.41	-0.9	0.95	0.31	0.81	0.83	0.73	0.81	0.81	0.77	0.76	0.76	0.94	-0.7	0.77		0.43	0.67	0.74	0.79	0.6	0.04	0.69
Non Currrent Assets Other	0.51	0.52	-0.06	0.4	-0.31	0.37	0.11	0.37	0.41	0.53	0.13	0.07	0.53	0.08	0.34	0.32	-0.46	0.35	0.43		0.5	0.5	0.18	0.53	0.42	0.56
Long Term Debt	0.91	0.9	-0.39	0.65	-0.76	0.64	0.16	0.51	0.72	0.94	0.38	0.52	0.94	0.3	0.57	0.56	-0.79	0.6	0.67	0.5		0.94	0.61	0.99	0.42	1.0
Cash And Short Term Investments	0.98	0.95	-0.53	0.8	-0.87	0.73	0.24	0.61	0.89	1.0	0.39	0.45	1.0	0.48	0.79	0.58	-0.94	0.81	0.74	0.5	0.94		0.81	0.92	0.57	0.95
Common Stock Shares Outstanding	0.82	0.8	-0.62	0.72	-0.89	0.82	0.35	0.64	0.93	0.79	0.52	0.49	0.8	0.77	0.96	0.62	-0.9	0.96	0.79	0.18	0.61	0.81		0.53	0.45	0.61
Non Current Liabilities Total	0.88	0.86	-0.35	0.63	-0.7	0.57	0.12	0.47	0.66	0.92	0.3	0.46	0.91	0.2	0.51	0.49	-0.75	0.54	0.6	0.53	0.99	0.92	0.53		0.43	0.99
Inventory	0.55	0.34	-0.51	0.82	-0.28	0.11	0.12	0.11	0.45	0.58	-0.42	-0.43	0.55	-0.07	0.58	-0.26	-0.7	0.59	0.04	0.42	0.42	0.57	0.45	0.43		0.44
Total Liab	0.93	0.92	-0.38	0.67	-0.77	0.66	0.17	0.55	0.75	0.96	0.37	0.5	0.95	0.31	0.6	0.57	-0.81	0.63	0.69	0.56	1.0	0.95	0.61	0.99	0.44

Click cells to compare fundamentals

Immunocore Holdings Account Relationship Matchups

Immunocore Holdings balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	36.5M	45.8M	58.1M	114.3M	178.6M	187.5M
Total Current Liabilities	55.0M	61.2M	83.1M	139.0M	212.2M	222.8M
Other Liab	48.1M	25.0M	6.5M	5.9M	5.3M	5.1M
Net Tangible Assets	14.8M	55.3M	171.5M	278.3M	320.1M	336.1M
Retained Earnings	(349.9M)	(481.4M)	(261.3M)	(744.7M)	(795.8M)	(756.0M)
Accounts Payable	7.9M	10.1M	14.5M	17.8M	25.1M	13.3M
Other Assets	6.5M	7.2M	7.5M	11.6M	10.4M	7.5M
Net Receivables	2.1M	24.8M	27.8M	61.4M	63.0M	37.1M
Other Stockholder Equity	20.1M	494.9M	1.0B	1.1B	1.2B	1.2B
Total Current Assets	152.9M	262.7M	391.9M	528.8M	929.9M	976.4M
Property Plant Equipment	54.9M	36.8M	31.5M	31.6M	36.4M	33.1M
Other Current Assets	27.7M	26.5M	13.7M	9.7M	41.0M	24.2M
Total Assets	197.2M	301.8M	435.5M	597.0M	1.0B	1.1B
Short Long Term Debt Total	63.9M	63.8M	69.3M	84.0M	41.7M	63.0M
Total Stockholder Equity	55.3M	171.5M	278.8M	368.8M	360.7M	205.3M
Property Plant And Equipment Net	36.8M	31.5M	31.6M	42.7M	47.7M	41.8M
Net Debt	(65.8M)	(174.1M)	(263.2M)	(358.6M)	(414.0M)	(393.3M)
Cash	129.7M	237.9M	332.5M	442.6M	455.7M	282.4M
Non Current Assets Total	44.3M	39.0M	43.6M	68.2M	79.6M	56.7M
Non Currrent Assets Other	4.2M	(31.5M)	7.2M	14.5M	17.1M	18.0M
Cash And Short Term Investments	129.7M	237.9M	332.5M	442.6M	820.4M	861.4M
Common Stock Shares Outstanding	31.8M	43.9M	45.7M	48.9M	50.0M	43.2M
Liabilities And Stockholders Equity	197.2M	301.8M	435.5M	597.0M	1.0B	1.1B
Non Current Liabilities Total	86.9M	69.0M	73.7M	89.1M	436.6M	458.4M
Capital Lease Obligations	27.2M	26.6M	29.8M	36.0M	41.7M	31.7M
Inventory	(21.2M)	(18.8M)	943K	4.5M	5.4M	5.7M
Total Liab	141.8M	130.2M	156.8M	228.2M	648.8M	681.2M
Net Invested Capital	92M	208.8M	318.3M	416.9M	751.7M	789.3M
Long Term Investments	591K	973K	165K	137K	123.3K	117.1K
Property Plant And Equipment Gross	36.8M	31.5M	31.6M	95.0M	103.1M	58.8M
Accumulated Other Comprehensive Income	163K	386.3M	334.8M	(36.3M)	(33.8M)	(32.1M)
Capital Stock	1K	88K	97K	135K	155.3K	163.0K
Net Working Capital	97.9M	201.5M	308.8M	389.8M	717.7M	753.6M
Current Deferred Revenue	27.1M	24.5M	6.4M	5.5M	5.4M	5.2M
Short Term Debt	12.6M	10.3M	(15.9M)	1.4M	3.1M	4.4M

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.

The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunocore Historical Balance Sheet

Immunocore Holdings Inventory

5.72 Million

About Immunocore Balance Sheet Analysis

Immunocore Holdings Balance Sheet Chart

Total Current Liabilities

Net Tangible Assets

Immunocore Holdings balance sheet Correlations

Immunocore Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunocore Holdings balance sheet Accounts

Pair Trading with Immunocore Holdings

Additional Tools for Immunocore Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Long Term Debt
Non Current Liabilities Total	+ 0.99	Long Term Debt

Cash And Short Term Investments	- 0.94	Net Debt
Cash	- 0.94	Net Debt
Net Debt	- 0.94	Total Assets
Net Debt	- 0.94	Total Current Assets
Retained Earnings	- 0.94	Total Current Liabilities
Net Debt	- 0.94	Other Current Liab